

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司

Tianjin TEDA Biomedical Engineering Company Limited

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 8189)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2017

This announcement is made at the request of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Reference is made to (i) the announcement of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) dated 26 March 2018 (the “**Annual Results Announcement**”) and the clarification announcement dated 29 March 2018 (the “**Clarification Announcement**”) in relation to the annual results of the Company and its subsidiaries (the “**Group**”) for the year ended 31 December 2017 and (ii) the annual report of the Group for the year ended 31 December 2017 (the “**Annual Report**”) posted on the respective websites of the Stock Exchange and the Company on 29 March 2018. Unless otherwise stated, capitalised terms used herein shall bear the same meanings as defined in the Annual Report.

The Company would like to provide the following additional information in respect of its acquisition (the “**Acquisition**”) of 51% stake of SJK Greater China Ltd. (“**SJKGC**”):

As disclosed in the circular of the Company dated 25 July 2016 in relation to the Acquisition, the Company had been provided profit guarantees by the vendor Shu Ju Ku Inc. (“**SJK**”) that the audited profit after tax of SJKGC in each of the three financial years of 2017, 2018 and 2019 (from 1 January to 31 December of each year) would not be less than US\$5,390,000, pursuant to the agreement (the “**Agreement**”) dated 16 April 2016 (as amended and supplemented by the supplemental agreement dated 25 April 2016) entered into among the Company, SJK and SJKGC. If the audited net profit after tax of SJKGC for any of the years is less than US\$5,390,000, SJK shall provide SJKGC with a compensation amount in cash equivalent to the difference between US\$5,390,000 and the audited net profit after tax achieved for that year, and guarantee that the cash dividend to be received by the Company for the year will not be less than US\$2,750,000, which is calculated according to the 51% shareholding ratio of the Company in SJKGC.

In view that the audited net profit after tax of SJKGC for the year ended 31 December 2017 was US\$3,010,000, the above profit guarantee for the year ended 31 December 2017 had not been fulfilled. In order to comply with the terms of the Agreement, the Company and SJK entered into a memorandum on 16 January 2018, pursuant to which SJK confirmed that the Company will have the right of priority and entitlement of cash dividend in the amount of US\$2,750,000 for the year ended 31 December 2017 and that the said dividend will be paid to the Company by 30 November 2018. The directors of the Company confirm that the above is in compliance with the terms of the Agreement.

The additional information above does not affect other information contained in the Annual Results Announcement, the Clarification Announcement and the Annual Report, and the other contents of the Annual Results Announcement, the Clarification Announcement and the Annual Report remain unchanged.

By order of the Board

Tianjin TEDA Biomedical Engineering Company Limited

Sun Li

Chairman

Tianjin, the PRC

26 April 2018

As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and Liu Renmu; the non-executive Directors of the Company are Cao Aixin, Feng Enqing, and Li Ximing; the independent non-executive Directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.